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inclusion of the symptoms. The heterogeneity in defining hypoglycaemia makes 
it difficult to compare the safety of interventions for their drug-induced hypogly-
caemia.
Diabetes/enDocrine DisorDers – cost studies
PDb24
buDget imPact analysis of long-acting insulin analogues in the 
PersPective of brazilian Public health system
Laranjeira FO, Silva EN, Pereira MG
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Objectives: To estimate the incremental budget impact of the reimbursement 
of long-acting insulin analogues (LAIA) for type 1 diabetes patients (T1DM) in 
Brazil. MethOds: A budget impact analysis (BIA) of LAIA in the Brazilian 
public health system compared to NPH human insulin was performed. The 
analysis’ time horizon was 5 years. The target population used the methodology 
of epidemiological demand, considering estimates of the International Diabetes 
Federation: 11.6 million diabetics of 20-79 years old x 5% T1DM plus 31100 chil-
dren and 10845 adolescents. It considered the incidence of 10.4/100,000 persons 
per year and mortality 23.15/1000 adults per year. The overall mean insulin dose 
was obtained from trials. For the human insulin, we considered the values of last 
purchase of the Ministry of Health. For both insulins, we got the average maxi-
mum sale price for government from CMED list. Then the bargaining power was 
calculated dividing the NPH’s maximum sale price by the Ministry’s purchase 
price, and we applied 50% of the bargaining power to the LAIA’s price. Market 
share was 50%, 60%, 70%, 80% and 80%. Results: The incremental budget 
impact of LAIA would be $93 million in the 1st year, considering 50% of target 
population, and reaching approximately $432 million for 80% of patients. In 5 
years, the calculated budget impact was $617 million. The sensitivity analysis 
indicates the prevalence and analogues prices as villains. cOnclusiOns: LAIA 
are available in Brazil since 2002, although to this day the public health system 
does not make it available to citizens. We can suggest that the reason for non-
coverage is the considerable budget impact, nevertheless our analysis, more com-
plex and with rational methodology, have shown less impact than the analysis 
used in the Ministry’s decision, which BIA was U$ 816 million for the coverage 
of LAIA.
PDb25
the nhs exPenDiture managing severe hyPoglycemia ePisoDes in tyPe 
2 Diabetic Patients in Portugal
Laires PA1, Conceição J1, Araújo F2, Dores J3, Silva C4, Radican L5, Nogueira AM1
1Merck Sharp & Dohme, Oeiras, Portugal, 2Hospital Beatriz Angelo, Loures, Portugal, 3Hospital 
Santo António, Porto, Portugal, 4Eurotrials, Scientific Consultants, Lisbon, Portugal, 5Merck Sharp 
& Dohme Corp., Rahway, NJ, USA
Objectives: Hypoglycemia is an acute complication of diabetes that increases 
the morbidity, mortality and disease costs. We aimed to estimate the annual NHS 
expenditure managing severe hypoglycemia episodes in type 2 diabetic patients 
in Portugal. MethOds: HIPOS-ER (Hypoglycemia in Portugal Observational Study 
– Emergency Room) study was an observational, cross-sectional, multicenter, 
hospital-based study conducted in seven centers of Portugal mainland within a 
period of 12 months (January 2013 - January 2014). Patient level data were used 
to quantify healthcare resource consumption related to emergency transporta-
tion, emergency department care and hospitalization. Unit costs for 2014 were 
extracted from official sources and reported in euros. Results: A total of 425,706 
admissions at the emergency room were registered in the participating hospitals 
within the shifts covered by HIPOS-ER study. Of these, 0.074% had diabetes type 2 
and were admitted due to an episode of hypoglycemia meaning that theoretically 
2.317 emergencies occur yearly in Portugal due to severe hypoglycemia in Type 
2 diabetic patients (out of an universe of 3.131.126 annual general emergencies 
in Portugal). Considering the HIPOS-ER estimated mean cost for managing this 
type of hypoglycemia (i.e. € 1,479), we expect that around 3.4 millions of euros 
per year are spent in treating this diabetes related complication at emergency 
rooms of NHS Portuguese hospitals. cOnclusiOns: Our estimation highlights 
the potential overall economic burden of severe hypoglycemias in Portugal, mean-
ing that this diabetes-related event must be taken in consideration by different 
healthcare stakeholders not only from strict clinical point of view, but also from 
and economic one. We conclude that severe hypoglycemic events represent a sub-
stantial cost for society and in particular for the hospitals of the National Health 
Service.
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Objectives: Background: The DPP4 inhibitors are among the newer, yet more estab-
lished, classes of diabetes medications. In the US these include: sitagliptin, saxa-
gliptin, linagliptin, and alogliptin. OBJECTIVE: The objective was to compare direct 
medical costs for patients taking DPP4-inhibitors. MethOds: Claims were extracted 
for Humana Medicare or Commercial plan members with > = 1 prescription filled 
for a DPP4-inhibitor between July 1, 2011 and March 31, 2013. The first prescription 
claim for a DPP4 established the index date and index medication, and 12-month 
pre- and post-index data were analyzed. The Diabetes Complications Severity Index 
(DCSI) assessed diabetes-related co-morbidities. Post-index costs (in 2013 US dol-
lars) were compared adjusting for pre-index costs, DCSI, pre-index insulin, age and 
gender using GLMs and p < 0.05. Results: Few patients were prescribed alogliptin. 
The final samples included 22,860 patients with Medicare coverage (17,292 sitagliptin; 
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Objectives: The aim of this study was to analyse which factors predict the real-
world macro-/microvascular event, hospitalisation and death risk in patients with 
type 2 diabetes mellitus (T2DM). MethOds: We used a German claims/clinical data 
set (AOK Plus) covering the years 2010-12. Factors associated with event risk were 
analysed by a Kaplan-Meier curve analysis and by multivariable Cox regression mod-
els. Results: 229,042 T2DM patients (mean age 70.2 years; mean CCI 6.03). A total 
of 66.3% of the sample had a mean systolic blood pressure of > 130mmHg (mean: 
135.56mmHg), 48.0% could be considered as obese (BMI> 30). The mean HbA1C in 
the sample was 7.00%; 11.1% of observed patients had a mean HbA1C< 6.0%, 75.3% 
< 7.5%, and 4.5% ≥ 9.0%. The mean observational period per patient from 01/04/2011 
until 31/12/2012 or until first observed all-cause event was 581.9 days (SD: 148.4). 
39,589 patients of the study sample (17.3%) were affected by at least one T2DM-
related event in this period (event frequency per 1,000 patient years: 82.7 macrovas-
cular events; 10.8 microvascular events; 28.4 hospitalisations with T2DM as main 
diagnosis; 40.7 deaths). Among factors that increased the composite event risk were 
patients’ age, male gender, the adapted Charlson-Comorbidity-Index, the adapted 
Diabetes-Complication-Severity Index, previous events, and number of prescribed 
chronic medications. For systolic blood pressure/HbA1C, a double-J/U-curve pattern 
was detected: HbA1C of 6-6.5% and systolic blood pressure of 130-140mmHg were 
associated with the lowest event risk, values below/above that range were associ-
ated with higher risk. However, this pattern was mainly driven by the death risk 
and was much less clearly observed for the macrovascular/microvascular/hospi-
talization risk and for young/less comorbid patients. cOnclusiOns: Both blood 
pressure and HbA1C seem to be very important treatment targets, especially in 
comorbid old patients. Both over- and under-treatment pose a threat to patients 
with type 2 diabetes mellitus.
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Objectives: Patients with type 2 diabetes mellitus (T2DM) display a unique skel-
etal phenotype with either normal or more frequently increased, bone mineral 
density and impaired structural and geometric properties. Alterations in bone 
material properties seem to be the predominant defect leading to increased bone 
fragility. A systematic review and meta-analysis of observational studies is con-
ducted to assess the association between T2DM and fracture risk. MethOds: A 
systematic literature search was performed in Medline and EMBASE databases. 
“Abstracts” from annual scientific meeting of various diabetes and bone and min-
eral societies were also searched to identify relevant studies. Studies reporting 
fracture risk in subjects with T2DM in comparison with subjects without diabetes 
were included. Heterogeneity was calculated by performing I2 statistics. Summary 
relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated 
using random-effects model. Results: Twelve studies met the inclusion criteria 
reporting 25,848 fracture events among 6,12,748 subjects without diabetes (4.2 %) 
and 8570 fracture events among 2,12,011 subjects with T2DM (4.0 %). The pooled 
relative risk (RR) of any fracture in subjects with T2DM was 0.91 (95% CI 0.75 – 1.11, 
p= 0.375). The pooled RR for any fractures in women with T2DM was 0.907 (95% 
CI 0.735- 1.118, 10 studies) compared to subjects without diabetes. The pooled RR 
for any fractures in men with T2DM was 0.868 (95% CI 0.738 to 1.022) compared 
to subjects without diabetes. Sensitivity analysis demonstrated stability of result 
after removing outliers. No publication bias was observed on visual analysis of 
funnel plot. cOnclusiOns: Our meta-analysis suggests that patients of T2DM 
are not at increased risk of incidence of fractures as compared to non diabetic 
subjects.
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Objectives: To examine the heterogeneity in the definitions of hypoglycaemia 
across Randomized Clinical Trials (RCTs) conducted with oral antidiabetic agents 
or insulin. MethOds: RCTs included in the Canadian Agency for Drugs and 
Technologies in Health (CADTH) reports for the second-line and third-line therapy 
for the patients with Type 2 Diabetes were examined. Definitions for overall, major, 
minor, severe, and nocturnal hypoglycaemia were extracted from 76 RCTs. The 
extracted definitions were compared to the definitions of the American Diabetes 
Association (ADA) and European Medicines Agency (EMA). Results: According to 
the ADA and the EMA, hypoglycaemia is defined as an event with a blood glucose 
(BG) ≤ 3.9mmol/L. Only 4 out of 76 studies adhered to the ADA/EMDA definition of 
hypoglycaemia. Generally, hypoglycaemia was defined as a status with BG rang-
ing from < 4 mmol/L to ≤ 2.8mmol/L. Only 17 out of 33 RCTs that defined severe 
hypoglycaemia adhered to the ADA/ EMDA definition. Severe hypoglycaemia was 
defined as a symptomatic condition that required the assistance of a third person 
for resuscitative actions, with or without BG values spanning from < 3.3 mmol/L to 
< 2.0 mmol/L. Major hypoglycaemia was defined as patients being unable to treat 
themselves, with or without a BG value ranging from < 3.1 mmol/L to ≤ 2.8 mmol/L. 
Nocturnal hypoglycaemia was vaguely defined when reported, as episodes occurring 
after evening injection and before breakfast, or between bedtime and morning, or 
any 6 hours or longer interval between 11pm and 8am. cOnclusiOns: Compared 
to the ADA and EMA proposed definitions of hypoglycaemia (BG≤ 3.9mmol/L), the 
studies included in our review had a substantial heterogeneity in their definitions 
of hypoglycaemia not only in terms of the BG values being used, but also with the 
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intROductiOn: Pre-pregnancy overweight and obesity have been proposed as 
risk factor to diabetes and hypertension during pregnancy. These medical com-
plications enhance the economic burden related to attend the pregnancy when 
it is classified as high risk pregnancy. Objectives: Identify diseases related to 
pre-gestational overweight and obesity in women with high risk pregnancy and 
estimate the economic burden to attend high risk pregnancy compared with nor-
mal pregnancy MethOds: Were studied 600 patients with high risk pregnancy to 
identify pre-pregnancy overweight and obesity and were estimated the cost related 
to the medical health care during pregnancy. Were calculated: mean, standard 
deviation, median, percentilar values, logistic regression and Odds Ratio with 
95% confidence interval. Were estimated costs for a hypothetical group of 600 
women with normal pregnancy, using Monte Carlo simulation method to compare 
economic burden between high risk pregnancy and normal pregnancy. Statistical 
differences were calculated with Student T test to paired samples. Groups were 
paired by maternal age and gestational age. Results: Pre-pregnancy body mass 
index mean was 29.59 (±6.42)kg/m2. The obesity was a risk factor to develop ges-
tational diabetes (OR: 1.95; IC95%: 1.39 to 2.76; p= 0.000). Were estimated in USD, 
to following costs: mean cost for prenatal health care: [$165.28 (±$52.39) in nor-
mal pregnancy; $801.18 (±$272.14), for high risk pregnancy, p= 0.000], mean cost 
for laboratory test [$ 138.41 (±$32.12) normal pregnancy; $895.91 (±$304.32) high 
risk pregnancy (p= 0.000)], delivery cost [$748.39 (±$340.51) normal pregnancy; 
$1,762.60 (±$513.88), p= 0.000 high risk pregnacy] and mean total cost $2,514.86 
(±$852.57), in normal pregnancy and $6,800.34 (±$3,829.82) high risk pregnancy 
(p= 0.000). cOnclusiOns: 75% pregnant women reach the pregnancy with preges-
tational overweight or obesity, and these conditions are risk factor to medical 
complications during pregnancy with significant higher costs derived from health 
care during pregnancy respect to women with normal pregnancy without pre-
pregnancy overweight or obesity
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Objectives: To compute the annual cost of FDC drugs used in the treatment of 
Type2 Diabetes Mellitus (T2DM) and study the variation in the costs. MethOds: 
Indian Council of Medical Research (ICMR) and International Diabetes Federation 
(IDF) guidelines were used to understand the treatment of T2DM. Current Index of 
Medical Specialities (CIMS) Oct- Jan 2015 issue and Indian Drug Review (IDR) issue 
1, Jan 2015 were used to capture the prices of medicines available in the Indian 
market. The annual cost of treatment and variation in the annual cost of drugs was 
studied. Results: Recommended first line FDC according to International Diabetes 
Federation is metformin + sulfonylurea. If we initiated the treatment with met-
formin + glimepiride (500mg + 1mg) OD, then annual cost of treatment was found 
to be Rs.438-2744. A maximum variation of 533% was noted in the least-highest cost 
of treatment. A minimum of 1% variation was observed for metformin + glipizide 
(2.5mg + 400mg) OD, among combination therapy in its least-highest cost of treat-
ment. Likewise, if the treatment is initiated with other combination therapy, say 
metformin + pioglitazone (500mg +15mg) BD, then annual cost of treatment was 
found to be Rs.1387-6935. This showed a maximum variation of 665% in its least-
highest cost of treatment. On the other hand metformin + voglibose (500 + 0.3mg) 
combination showed a minimum price variation of 86% only. cOnclusiOns: It was 
concluded that a maximum of 6 fold variation was observed in the least-highest 
costs of treatment with metformin + voglibose (500mg + 0.3mg). A wide varia-
tion exist in the minimum and maximum price of anti-diabetic FDC manufactured 
across the different brands available in the Indian market.
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Objectives: Diabetes Mellitus (DM) is a chronic-degenerative disease associated 
with a high risk of chronic complications and co-morbidities. The aim of this study 
is to estimate the average annual cost incurred by the National Health Service 
(NHS) for the treatment of DM stratified by patients’ comorbidities. Moreover, the 
model estimate the economic impact implementing good clinical practice for the 
management of diabetic patients. MethOds: Data were extrapolated from admin-
istrative database of the Marche Region and specific inclusion and exclusion criteria 
were developed from clinical board in order to estimate patients with DM only, 
DM+1, DM+2, DM+3 and DM+4 comorbidities (cardiovascular disease, neuropathy, 
nephropathy and retinopathy). Regional data were considered a good proxy for 
implementing a previous developed Cost of Illness model from NHS perspective 
already published. Scenario analysis were considered to estimate the economic 
impact of good clinical practice implementation in the treatment of DM and its 
comorbidities in Italy. Results: The model estimated an average number of dia-
betic patients per year in the Marche region of 86.155 (5.5% of population) from 
2008-2011. Mean costs per patients with DM only, DM+1, DM+2, DM+3 and DM+4 
comorbidities were € 179, € 1,560, € 2,736, € 8,494 and € 21,321, respectively. From the 
NHS perspective, the total economic burden of DM in Italy amounted to € 8.5 billion/
year (22% for drugs, 74% for hospitalization and 4% for visits). Scenario analysis 
demonstrate that implementation of good clinical practice could save over € 700 
million year. cOnclusiOns: This model is the first study that consider real world 
data and CoI model to estimate the economic burden of DM and its comorbidities 
from the NHS perspective. Integrated management of the diabetic patient could be 
a good driver for the reduction of the costs of this disease in Italy.
4,282 saxagliptin and 1,286 linagliptin) and 3,229 patients with Commercial coverage 
(2,368 sitagliptin; 643 saxagliptin and 218 linagliptin). Patient demographics were 
similar for index medications: Medicare cohort – mean age 70-72; female 50-52% 
Commercial cohort – mean age 55-56; female 44%. Patients on linagliptin showed 
a higher co-morbidity level at baseline (Medicare DCSI = 3.0 vs 2.4/2.2; Commercial 
DCSI = 1.2 vs. 0.9/0.9), higher use of pre-index insulin (Medicare 22% vs 15%/14%; 
Commercial 18% vs 11%/10%) and higher pre-index costs (Medicare mean $14,448 vs 
$11,818/$10,399; Commercial mean $13,868 vs $9,357/$8,223) than sitagliptin or saxa-
gliptin cohorts, respectively. When controlling for other factors, post-index costs were 
similar between the medication cohorts - Medicare: sitagliptin $13,913; saxagliptin 
$13,651; linagliptin $13,859; Commercial: sitagliptin $11,677; saxagliptin$12,059; lina-
gliptin $11,163. cOnclusiOns: For Medicare and Commercial populations, members 
on linagliptin may have been more complex patients (higher DCSI, more use of insulin, 
higher pre-index costs). When controlling for baseline factors, 12-month post-index 
direct medical costs were similar between index DPP4 medications.
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Objectives: to compare the healthcare utilization and costs in the year before and 
after randomization among participants of a clinical trial assessing the effective-
ness of nurse-led telecoaching in optimizing diabetes control in Belgium. MethOds: 
Patients were affiliates of the Independent Sickness Funds with type 2 diabetes 
selected by hypoglycaemic agent consumption, invited into the study and randomized 
to telecoaching or usual care. The intervention was delivered by diabetes educators 
in five telephone sessions spread over 6 months. Costs of the intervention were col-
lected along the trial. Information on resource utilization was extracted from the 
database of the sickness funds and the between group difference in change was 
analyzed per service category. Results: 287 patients enrolled in the intervention 
and 287 in the control group. The average cost of the intervention was € 300.64. At 
baseline, the annual mean healthcare cost (CI) was € 5,543 (4,410–6,677) in the inter-
vention and € 4,101 (3,375–4,827) in the control group and in the year of the trial € 5,516 
(4,630 –6,402) and 4,757 (3,892–5,622), implying a change of -1% and +16% respectively. 
Hospitalizations affected 19% and 15% of patients in the intervention and control 
group, accounting for 33% and 23% of total costs at baseline, respectively. In the year 
of the trial, changes were observed in the intervention and control group respec-
tively in the number of hospital admissions: -27% and +36% (p= .048), endocrinologist 
consultations: +35% and -10% (p= .023), HbA1c tests: +9% and -12% (p< .0001), lipid 
tests: +8% and -16% (p< .0001) and consumption of lipid modifying agents: +14% and 
+1% (p= .042). cOnclusiOns: Participants of the nurse-led telecoaching program 
aimed at improvement of diabetes selfmanagement demonstrated increased costs for 
guideline recommended outpatient care and a decrease in the number and costs of 
hospital admissions compared to controls. These findings are hypothesis generating.
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Objectives: To compare drug acquisition costs and most commonly used doses 
between two GLP-1 agonists, once-weekly exenatide (QW) 2.0 mg with no dose titra-
tion, and once-daily liraglutide with a recommended starting dose of 0.6 mg and 
titration to 1.2 mg or 1.8 mg over 2-weeks. MethOds: This cohort study included 
patients with type 2 diabetes initiating exenatide QW or liraglutide between Jan 2012 
and Feb 2014, who had > 6-months of preceding coverage in U.S. healthcare claims 
database. During the 6 months following treatment initiation, drugs dispensed and 
associated pharmacy costs were compared between exenatide QW 2 mg dose and 
liraglutide dose subgroups, defined by maintenance dose at 60 days. Results: The 
exenatide QW (N= 3,217) and liraglutide (N= 10,954) cohorts had comparable charac-
teristics at baseline. Due to titration recommendations, the majority of the liraglu-
tide patients received 1.8 mg per day dose (56.2%), while 2.2% and 41.6% received 0.6 
mg and 1.2 mg per day, respectively, by the end of follow-up. Comparing costs asso-
ciated with exenatide QW versus specific liraglutide maintenance doses, patients 
on liraglutide 1.8 mg per day had higher average pharmacy costs of $3,827 (95%CI: 
$3,752-$3,902) compared to exenatide QW costs of $3,556 (95% CI: $3,462-$3,649), and 
higher average pharmacy costs associated with all antihyperglycemic drug dispens-
ings, $2,543 (95%CI: $2,502 - $2,585), compared to exenatide QW costs $2,345 (95%CI: 
$2,290 - $2,401). cOnclusiOns: Exenatide QW, which does not require titration, 
provided savings in both overall pharmacy costs and costs of antihyperglycemic 
drugs compared to the majority (56.2%) of liraglutide patients who required titration 
to the highest dose of 1.8 mg. Lower pharmacy costs in addition to overall safety 
and efficacy profile, convenience of no titration, and once weekly dosing, provide a 
good cost-benefit value for patients treated with exenatide QW.
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